Deals In Depth: March 2019
Executive Summary
Alexion signed two $600m-plus alliances, with Zealand Pharma and Affibody, that made it into the top five deals by value. Thermo Fisher grew its capabilities in cell and gene therapy manufacturing by acquiring Brammer Bio for $1.7bn. A $3.5bn private placement by AstraZeneca boosted pharma financing.
You may also be interested in...
EU Gene Therapy Submissions, Approvals Expected To Pick Up In 2021
Coming year could feature first-time approvals in the EU for at least five gene therapies.
Deals In Depth: February 2020
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
Deals Shaping The Medical Industry, March 2020
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2020.
Need a specific report? 1000+ reports available
Buy Reports